Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · IEX Real-Time Price · USD
6.16
-0.15 (-2.38%)
At close: Jul 2, 2024, 4:00 PM
6.15
-0.01 (-0.16%)
After-hours: Jul 2, 2024, 7:36 PM EDT
Sight Sciences Revenue
Sight Sciences had revenue of $81.50M in the twelve months ending March 31, 2024, with 8.27% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $19.27M with 2.34% year-over-year growth. In the year 2023, Sight Sciences had annual revenue of $81.06M with 13.63% growth.
Revenue (ttm)
$81.50M
Revenue Growth
+8.27%
P/S Ratio
3.76
Revenue / Employee
$380,822
Employees
214
Market Cap
306.50M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 81.06M | 9.73M | 13.63% |
Dec 31, 2022 | 71.33M | 22.38M | 45.70% |
Dec 31, 2021 | 48.96M | 21.32M | 77.12% |
Dec 31, 2020 | 27.64M | 4.29M | 18.38% |
Dec 31, 2019 | 23.35M | 15.82M | 210.07% |
Dec 31, 2018 | 7.53M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Nevro | 430.75M |
OraSure Technologies | 304.64M |
Cerus | 191.72M |
Xeris Biopharma Holdings | 171.36M |
SOPHiA GENETICS | 64.18M |
Foghorn Therapeutics | 33.90M |
TScan Therapeutics | 14.81M |
SGHT News
- 22 days ago - Sight Sciences Announces the Release of its First Sustainability Report - GlobeNewsWire
- 5 weeks ago - Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis - GlobeNewsWire
- 5 weeks ago - Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma - GlobeNewsWire
- 2 months ago - Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance - GlobeNewsWire
- 2 months ago - Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery - GlobeNewsWire
- 2 months ago - Sight Sciences to Report First Quarter Financial Results on May 2, 2024 - GlobeNewsWire
- 2 months ago - Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma - GlobeNewsWire
- 3 months ago - Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - GlobeNewsWire